Immunovant annual depreciation and amortization
2019
2020
2021
2022
2023
2024
2025
2026
Immunovant Depreciation & Amortization Growth & History (IMVT)
Immunovant's depreciation and amortization was $409,000 for fiscal 2026.
View full Immunovant company overviewImmunovant annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | $409,000 | $32,000 | +8.49% |
| 2025 | 2025-03-31 | $377,000 | $146,000 | +63.20% |
| 2024 | 2024-03-31 | $231,000 | $38,000 | +19.69% |
| 2023 | 2023-03-31 | $193,000 | $67,000 | +53.17% |
| 2022 | 2022-03-31 | $126,000 | $61,000 | +93.85% |
| 2021 | 2021-03-31 | $65,000 | $44,000 | +209.52% |
| 2020 | 2020-03-31 | $21,000 | $11,000 | +110.00% |
| 2019 | 2019-03-31 | $10,000 | — | — |
Immunovant quarterly depreciation and amortization
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q1.26
Q2.26
Q3.26
Q4.26
Q1.27
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q1 2027 | 2026-06-30 | $92,000 | −$15,000 | −14.02% |
| Q4 2026 | 2026-03-31 | $96,000 | — | — |
| Q3 2026 | 2025-12-31 | $101,000 | $2,000 | +2.02% |
| Q2 2026 | 2025-09-30 | $105,000 | $16,000 | +17.98% |
| Q1 2026 | 2025-06-30 | $107,000 | $27,000 | +33.75% |
| Q3 2025 | 2024-12-31 | $99,000 | $41,000 | +70.69% |
| Q2 2025 | 2024-09-30 | $89,000 | $33,000 | +58.93% |
| Q1 2025 | 2024-06-30 | $80,000 | $27,000 | +50.94% |
| Q3 2024 | 2023-12-31 | $58,000 | $9,000 | +18.37% |
| Q2 2024 | 2023-09-30 | $56,000 | $10,000 | +21.74% |
| Q1 2024 | 2023-06-30 | $53,000 | $9,000 | +20.45% |
| Q3 2023 | 2022-12-31 | $49,000 | $16,000 | +48.48% |
| Q2 2023 | 2022-09-30 | $46,000 | $18,000 | +64.29% |
| Q1 2023 | 2022-06-30 | $44,000 | $18,000 | +69.23% |
| Q3 2022 | 2021-12-31 | $33,000 | $14,000 | +73.68% |
| Q2 2022 | 2021-09-30 | $28,000 | $14,000 | +100.00% |
| Q1 2022 | 2021-06-30 | $26,000 | $16,000 | +160.00% |
| Q3 2021 | 2020-12-31 | $19,000 | $14,000 | +280.00% |
| Q2 2021 | 2020-09-30 | $14,000 | $9,000 | +180.00% |
| Q1 2021 | 2020-06-30 | $10,000 | $5,000 | +100.00% |
| Q3 2020 | 2019-12-31 | $5,000 | — | — |
| Q2 2020 | 2019-09-30 | $5,000 | — | — |
| Q1 2020 | 2019-06-30 | $5,000 | — | — |
Immunovant depreciation and amortization trends
Over the last five fiscal years, Immunovant's depreciation and amortization increased from $65,000 to $409,000, a change of $344,000. The latest reported quarter, Q1 2027, shows $92,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Immunovant source filings ↗